Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial | Zendy

Alan Winston | Zendy; Janaki Amin | Zendy; Amanda Clarke | Zendy; Laura Else | Zendy; Alieu Amara | Zendy; Andrew Owen | Zendy; Tristan Barber | Zendy; Heiko Jessen | Zendy; Anchalee Avinghsa | Zendy; Ploenchan Chetchotisakd | Zendy; Saye Khoo | Zendy; David A. Cooper | Zendy; Sean Emery | Zendy; Rebekah Puls | Zendy; Dianne Carey | Zendy; Kymme Courtney-Vega | Zendy; Carlo Dazo | Zendy; Anna Donaldson | Zendy; Núria Espinosa | Zendy; Peeraporn Kaew-on | Zendy; Praphan Phanupak | Zendy; Kanitta Pussadee | Zendy; Louise Tomkins | Zendy; Sasiwimol Ubolyam | Zendy; Praphan Phanuphak | Zendy; Carmen Zedlack | Zendy; Brian Gazzard | Zendy; Serge Federle | Zendy; Sophie Scott | Zendy; Borja Mora-Peris | Zendy; Ken Legg | Zendy; Scott Mullaney | Zendy; David Back | Zendy; Sujan Dilly Penchala | Zendy; Steve Kaye | Zendy; Anthony D. Kelleher | Zendy; Philip Cunningham | Zendy; Kate Merlin | Zendy; Julie Yeung | Zendy; Ansari Shaik | Zendy; Bertha Fsadni | Zendy; Alex Carrera | Zendy; Melanie Lograsso | Zendy

Open Access

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Author(s) -

Alan Winston,

Janaki Amin,

Amanda Clarke,

Laura Else,

Alieu Amara,

Andrew Owen,

Tristan Barber,

Heiko Jessen,

Anchalee Avinghsa,

Ploenchan Chetchotisakd,

Saye Khoo,

David A. Cooper,

Sean Emery,

Rebekah Puls,

Dianne Carey,

Kymme Courtney-Vega,

Carlo Dazo,

Anna Donaldson,

Núria Espinosa,

Peeraporn Kaew-on,

Praphan Phanupak,

Kanitta Pussadee,

Louise Tomkins,

Sasiwimol Ubolyam,

Praphan Phanuphak,

Carmen Zedlack,

Brian Gazzard,

Serge Federle,

Sophie Scott,

Borja Mora-Peris,

Ken Legg,

Scott Mullaney,

David Back,

Sujan Dilly Penchala,

Steve Kaye,

Anthony D. Kelleher,

Philip Cunningham,

Kate Merlin,

Julie Yeung,

Ansari Shaik,

Bertha Fsadni,

Alex Carrera,

Melanie Lograsso

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu976

Subject(s) - efavirenz , cerebrospinal fluid , medicine , pharmacokinetics , gastroenterology , reverse transcriptase inhibitor , pharmacology , toxicity , randomized controlled trial , sida , viral load , virology , virus , antiretroviral therapy , viral disease

The optimal penetration of antiretroviral agents into the central nervous system may be a balance between providing adequate drug exposure to inhibit human immunodeficiency virus (HIV) replication while avoiding concentrations associated with neuronal toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research